NDAORALTABLET
Approved
Sep 2005
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Data completeness
7/8 — Comprehensive
ANGELIQ (drospirenone and estradiol) by Bayer is estrogen receptor agonists [moa]. Approved for progestin [epc]. First approved in 2005.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANGELIQ is an oral tablet combining drospirenone (a progestin) and estradiol (an estrogen) approved in 2005 for hormone replacement therapy in menopausal women. It works via estrogen receptor agonism to relieve vasomotor symptoms and other menopausal manifestations. The combination formulation addresses both estrogen deficiency and provides progestin-mediated endometrial protection.
$0.427MPart D
Peak5.1 years to LOEANGELIQ remains in peak lifecycle with modest Medicare spending ($427K in 2023), indicating a mature but stable product with limited growth potential and a focused commercial team.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Progestin
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia
Started May 2017
1,570 enrolled
Menopause
Angeliq Regulatory Post Marketing Surveillance
Started Jun 2007
4,078 enrolled
Postmenopausal PeriodOsteoporosis, Postmenopausal
Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension
Started Jan 2007
92 enrolled
PostmenopauseHypertensionPre-Hypertension
Efficacy and Tolerability of Angeliq in Thai Women
Started Sep 2005
55 enrolled
Postmenopause
Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women
Started Apr 2004
750 enrolled
HypertensionPostmenopause
Worked on ANGELIQ at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.